MBRX Earnings

MBRX reported its FY2025Q2 earnings on 2025-08-12, showcasing a revenue of against an estimate of , resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.39 by 0% . The stock experienced a 6.45% price change on the earnings day and a 9.73% change over the next five days, reflecting market reactions to the results.

Following MBRX's FY2025Q2 earnings announcement on 2025-08-12, the stock price moved by 6.45% on the day of the release. Over the subsequent five days, it saw a 9.73% change. Historically, MBRX's stock price tends to shift by an average of -0.48% in the 10 days leading up to earnings and -6.77% in the 10 days following, providing insight into potential market.

For , analysts estimate MBRX’s annual revenue to reach undefined, while the EPS is projected at -6.42. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 26.75% and EPS estimates No Change by % over the past three months, indicating analyst expectation in the company’s performance.

The correlation between MBRX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 26.75%, while EPS estimates moved No Change by % . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, MBRX's stock price typically moves by -0.48% in the 10 days before its earnings and -6.77% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -6.42 and revenue of undefined.

The earnings call presents mixed signals. Positive factors include the EMA approval, new drug name recognition, and patent protection for Annamycin. However, the need for $15 million in funding and regulatory risks pose significant challenges. The Q&A section reveals uncertainties, particularly concerning EU approval timelines and R&D expenses. The small market cap suggests potential volatility, but the lack of clear positive catalysts and financial uncertainties balance the sentiment, leading to a neutral prediction.